Vext Science, Inc. Logo

Vext Science, Inc.

VEXT.CN

(2.2)
Stock Price

0,20 CAD

-9.68% ROA

-8.12% ROE

-5.06x PER

Market Cap.

37.707.269,63 CAD

44.21% DER

0% Yield

-20.8% NPM

Vext Science, Inc. Stock Analysis

Vext Science, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vext Science, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.5x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

3 ROE

ROE in an average range (10.39%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (8.39%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 DER

The stock has a reasonable amount of debt compared to its ownership (55%), suggesting a balanced financial position and a moderate level of risk.

6 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (1) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Vext Science, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vext Science, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Vext Science, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vext Science, Inc. Revenue
Year Revenue Growth
2017 14.848.730
2018 18.476.269 19.63%
2019 22.322.568 17.23%
2020 25.193.958 11.4%
2021 37.243.709 32.35%
2022 35.410.636 -5.18%
2023 32.397.140 -9.3%
2023 34.812.311 6.94%
2024 33.707.712 -3.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vext Science, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 70.772
2018 107.354 34.08%
2019 112.962 4.96%
2020 158.685 28.81%
2021 150.064 -5.74%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vext Science, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 1.737.331
2018 1.820.792 4.58%
2019 4.285.063 57.51%
2020 4.656.217 7.97%
2021 5.283.941 11.88%
2022 9.822.321 46.2%
2023 10.791.496 8.98%
2023 13.840.538 22.03%
2024 12.055.436 -14.81%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vext Science, Inc. EBITDA
Year EBITDA Growth
2017 6.134.734
2018 5.506.177 -11.42%
2019 4.424.050 -24.46%
2020 5.354.200 17.37%
2021 12.774.279 58.09%
2022 15.363.491 16.85%
2023 1.811.488 -748.11%
2023 1.838.528 1.47%
2024 872.904 -110.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vext Science, Inc. Gross Profit
Year Gross Profit Growth
2017 8.633.368
2018 9.654.954 10.58%
2019 10.065.747 4.08%
2020 11.199.763 10.13%
2021 18.685.495 40.06%
2022 23.098.448 19.1%
2023 11.218.968 -105.89%
2023 12.038.426 6.81%
2024 6.215.968 -93.67%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vext Science, Inc. Net Profit
Year Net Profit Growth
2017 4.107.232
2018 3.748.562 -9.57%
2019 2.793.324 -34.2%
2020 2.125.068 -31.45%
2021 4.986.719 57.39%
2022 10.919.280 54.33%
2023 -7.352.812 248.5%
2023 4.398.447 267.17%
2024 -17.560.140 125.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vext Science, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vext Science, Inc. Free Cashflow
Year Free Cashflow Growth
2017 737.208
2018 906.715 18.69%
2019 -5.653.028 116.04%
2020 -964.903 -485.86%
2021 -7.102.345 86.41%
2022 -2.937.558 -141.78%
2023 1.687.639 274.06%
2023 10.220 -16413.1%
2024 -1.202.133 100.85%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vext Science, Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 1.869.036
2018 2.409.636 22.43%
2019 -393.313 712.65%
2020 3.098.562 112.69%
2021 11.681.311 73.47%
2022 5.922.825 -97.23%
2023 4.424.704 -33.86%
2023 360.374 -1127.81%
2024 -592.031 160.87%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vext Science, Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 1.131.828
2018 1.502.921 24.69%
2019 5.259.715 71.43%
2020 4.063.465 -29.44%
2021 18.783.656 78.37%
2022 8.860.383 -112%
2023 2.737.065 -223.72%
2023 350.154 -681.67%
2024 610.102 42.61%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vext Science, Inc. Equity
Year Equity Growth
2017 8.774.713
2018 17.000.575 48.39%
2019 25.673.198 33.78%
2020 36.313.120 29.3%
2021 59.393.563 38.86%
2022 71.918.522 17.42%
2023 94.982.275 24.28%
2023 70.961.648 -33.85%
2024 86.998.831 18.43%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vext Science, Inc. Assets
Year Assets Growth
2017 13.840.997
2018 23.434.185 40.94%
2019 38.780.494 39.57%
2020 55.454.661 30.07%
2021 83.704.108 33.75%
2022 120.516.974 30.55%
2023 149.559.806 19.42%
2023 118.223.181 -26.51%
2024 144.877.362 18.4%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vext Science, Inc. Liabilities
Year Liabilities Growth
2017 5.066.284
2018 6.433.610 21.25%
2019 13.107.296 50.92%
2020 19.141.541 31.52%
2021 24.310.545 21.26%
2022 48.598.452 49.98%
2023 54.577.531 10.96%
2023 47.261.533 -15.48%
2024 57.878.531 18.34%

Vext Science, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.14
Net Income per Share
-0.03
Price to Earning Ratio
-5.06x
Price To Sales Ratio
1.13x
POCF Ratio
71.14
PFCF Ratio
-25.35
Price to Book Ratio
0.4
EV to Sales
2.18
EV Over EBITDA
-35.49
EV to Operating CashFlow
147.67
EV to FreeCashFlow
-48.93
Earnings Yield
-0.2
FreeCashFlow Yield
-0.04
Market Cap
0,04 Bil.
Enterprise Value
0,07 Bil.
Graham Number
0.47
Graham NetNet
-0.18

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
-0.07
ROE
-0.08
Return On Assets
-0.05
Return On Capital Employed
-0.13
Net Income per EBT
1.13
EBT Per Ebit
0.36
Ebit per Revenue
-0.51
Effective Tax Rate
-0.13

Margins

Sales, General, & Administrative to Revenue
0.47
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.23
Operating Profit Margin
-0.51
Pretax Profit Margin
-0.18
Net Profit Margin
-0.21

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
4.02
Capex to Revenue
0.06
Capex to Depreciation
0.15
Return on Invested Capital
-0.15
Return on Tangible Assets
-0.1
Days Sales Outstanding
42.31
Days Payables Outstanding
53.34
Days of Inventory on Hand
192.21
Receivables Turnover
8.63
Payables Turnover
6.84
Inventory Turnover
1.9
Capex per Share
0.01

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,35
Tangible Book Value per Share
0.06
Shareholders Equity per Share
0.35
Interest Debt per Share
0.17
Debt to Equity
0.44
Debt to Assets
0.27
Net Debt to EBITDA
-17.1
Current Ratio
1.58
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
124888156
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.51
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
13345908.5
Debt to Market Cap
1.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vext Science, Inc. Dividends
Year Dividends Growth

Vext Science, Inc. Profile

About Vext Science, Inc.

Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. The company is involved in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. It also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen and Pure Touch Botanicals brands. In addition, the company offers Vapen clear infused products, THC chocolate bars, THC syrup, THC snacks, candies, and gummies under Vapen Kitchens brand. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona .

CEO
Mr. Eric J. Offenberger
Employee
173
Address
4152 North 39th Avenue
Phoenix, 85019

Vext Science, Inc. Executives & BODs

Vext Science, Inc. Executives & BODs
# Name Age
1 Jonathan Ross
Investor Relations Officer
70
2 Mr. Jason Thai Nguyen
Founder & Executive Chairman
70
3 Mr. Eric J. Offenberger
Chief Executive Officer, Chief Operating Officer, President & Director
70
4 Mr. Trevor Smith
Chief Financial Officer
70
5 Nalee Pham
Company Secretary
70

Vext Science, Inc. Competitors

4Front Ventures Corp. Logo
4Front Ventures Corp.

FFNT.CN

(0.5)
Ayr Wellness Inc. Logo
Ayr Wellness Inc.

AYR-A.CN

(1.5)
C21 Investments Inc. Logo
C21 Investments Inc.

CXXI.CN

(1.0)
Columbia Care Inc. Logo
Columbia Care Inc.

CCHW.CN

(1.0)
Jushi Holdings Inc. Logo
Jushi Holdings Inc.

JUSH.CN

(0.5)